Faisal Zain is a distinguished leader in the biopharmaceutical sector, renowned for his strategic oversight in oncology drug development and the manufacturing of complex therapeutic platforms. With a career dedicated to bridging the gap between innovative clinical research and commercial viability, he has become a pivotal voice in the evolution of next-generation immunotherapies. In this conversation, we explore the industry-wide shift toward dual-mechanism drugs, focusing on AstraZeneca’s substantial $2 billion investment in Summit Therapeutics and the clinical promise of bispecific antibodies to redefine the standard of care in cancer treatment.
How do bispecific antibodies like ivonescimab fundamentally change the oncology landscape compared to established blockbusters like Keytruda?
The emergence of ivonescimab represents a significant leap from the single-target approach that has dominated the market for years. By binding simultaneously to PD-1 on T cells and VEGF on cancer cells, this molecule doesn’t just unlock the immune system; it actively disrupts the blood supply the tumor needs to survive. We saw the weight of this dual action in the Phase 3 trial results out of China, where ivonescimab actually outperformed Merck’s heavyweight PD-1 inhibitor, Keytruda, in a head-to-head lung cancer study. It is a bold move to challenge such a dominant therapy, but the data suggests that hitting these two distinct pathways creates a synergy that a mono-therapy simply cannot match. For clinicians and patients, this means the potential for more durable responses in an arena where we are constantly fighting against the clock.
What specific advantages does the combination of a PD-1/VEGF bispecific antibody offer when paired with an antibody-drug conjugate like AstraZeneca’s sone-ve?
This combination strategy is designed to solve one of our most persistent problems: drug resistance in solid tumors. When we look at AstraZeneca’s experimental ADC, sonesitatug vedotin—or sone-ve—it has already shown a statistically significant improvement in overall survival for patients with CLDN18.2-positive gastric cancers. However, the real magic happens when you introduce a bispecific like ivonescimab, which alters the tumor microenvironment to make it far more receptive to the ADC’s payload. This one-two punch effectively primes the “soil” of the tumor so the ADC can deliver its toxic “seed” more efficiently. We are eagerly anticipating the detailed data presentation at the upcoming European Society for Medical Oncology conference in late October, as it could validate this pairing as the new backbone of gastrointestinal cancer treatment.
Why would a pharmaceutical giant like AstraZeneca choose an equity investment and research collaboration over an outright acquisition of Summit Therapeutics?
It is a sophisticated chess move that balances high-stakes innovation with financial prudence. By purchasing 108,955 shares at $18.36 each—representing an 18.6% premium—AstraZeneca is securing a front-row seat to ivonescimab’s development while keeping their options open. This $2 billion bet allows them to lead the sponsorship of planned clinical trials and deeply integrate their own ADC portfolio without the immediate overhead of an acquisition. History shows that companies like Merck have used similar collaboration data to eventually license competing drugs, so this “test-and-learn” approach is very much in the industry’s DNA. It gives AstraZeneca the agility to pivot if the Western clinical trials, which Summit is conducting across the Americas, Europe, and Japan, mirror the success seen in the Chinese pivotal studies.
With companies like AbbVie, Bristol Myers Squibb, and Pfizer also pursuing bispecific deals, how competitive has the race for PD-1/VEGF dominance become?
The industry is currently in the middle of a massive flurry of dealmaking, and the competition is nothing short of intense. Everyone is racing to secure a foothold in this class because the potential applications extend far beyond just lung or gastric cancers; we are already seeing pivotal data in areas like biliary tract cancer, where preliminary results have shown significant improvement. Even biotech firms like Crescent Biopharma are getting into the mix, licensing ADCs to pair with their own bispecific candidates. This tells us that the “next-generation immunotherapy” is no longer a distant goal but a current reality that is reshaping how every major player structures their pipeline. The sheer volume of capital being poured into these dual-targeting therapies underscores a collective belief that this is the future of oncology.
What is your forecast for the role of bispecific antibodies in the global oncology market over the next few years?
I expect bispecific antibodies to transition from “promising alternatives” to the foundational backbone of most solid tumor treatment regimens. We are moving away from the era of “one-size-fits-all” inhibitors and into a period of highly engineered multi-specifics that can navigate the complexity of the tumor microenvironment. Within the next few cycles of clinical readouts, we will likely see these drugs moving into first-line settings for a variety of cancers, potentially displacing the current generation of PD-1 blockbusters entirely. As the manufacturing processes for these complex molecules become more efficient and we gather more global data outside of China, the accessibility of these treatments will skyrocket. The industry’s focus is clearly shifting toward these versatile platforms because they offer the precision and power necessary to finally overcome the hurdles of tumor resistance and improve long-term patient survival.
